RPT-Sanofi dengue vaccine promising but questions remain

viernes 11 de julio de 2014 03:55 GYT

(Repeats with no change to text to reach more subscribers)

* Currently no vaccine for expanding mosquito-borne disease

* 56 pct efficacy hides mixed picture by virus strain

* Vaccine poor at protecting young children, most at risk

* Likely to serve endemic countries more than travellers

By Natalie Huet

PARIS, July 11 (Reuters) - The first vaccine against dengue fever, from France's Sanofi, provided moderate protection in a large clinical study, but questions remain as to how well it can help fight the world's fastest-growing tropical disease.

The late-stage trial involved 10,275 healthy children aged 2-14 across five countries in Asia, a region that accounts for over two-thirds of the mosquito-borne disease's global burden.

Sanofi had already disclosed in April that its vaccine reduced the incidence of dengue fever by 56 percent in the Asian study, without giving details. The full findings were published online on Friday in The Lancet medical journal.   Continuación...